CDIO logo

CARDIO DIAGNOSTICS HOLDINGS

CDIONASDAQ
🏆 #5126 by market capUS Equity
$1.90▲ $0.03 (+1.33%)
Live
🔔
Track CDIO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.3%
7d▼ 1.0%
14d▼ 6.4%
30d▲ 2.7%
ytd▼ 34.4%
1y▼ 52.9%
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
-25.9%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
382.7x
Expensive
Otter Score
76
Good

Trading Snapshot

Day Range
$1.89 – $1.91
52-Week Range
$0.97 – $7.91
Volume
$2.67B
Avg Volume
$2.75B
Shares Outstanding
3.0M
Next Earnings
Nov 2, 2026

Fundamentals Snapshot

Annual Revenue
$14,825
Last Q Revenue
$5,360
P/E Ratio
—
P/S Ratio
382.7x
EPS (TTM)
$-2.92
Dividend Yield
—
Dilution (1yr)
−96.0%

Why Investors Own CDIO

  • ✓High-growth profile — revenue up +52.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 43% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CDIO logo

CARDIO DIAGNOSTICS HOLDINGS

CDIO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$15K▼ −57.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▼ −22.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▲ +9.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.8M▼ −96.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▼ −$2M YoY
StockOtter · stockotter.space

About CARDIO DIAGNOSTICS HOLDINGS

Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2025

Latest News & Updates

🚀
Bloomberg·2h ago

CARDIO DIAGNOSTICS HOLDINGS tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift CDIO price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

CARDIO DIAGNOSTICS HOLDINGS announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.